MX2022006891A - Terapia combinada con liv1-adc y antagonista de pd-1. - Google Patents
Terapia combinada con liv1-adc y antagonista de pd-1.Info
- Publication number
- MX2022006891A MX2022006891A MX2022006891A MX2022006891A MX2022006891A MX 2022006891 A MX2022006891 A MX 2022006891A MX 2022006891 A MX2022006891 A MX 2022006891A MX 2022006891 A MX2022006891 A MX 2022006891A MX 2022006891 A MX2022006891 A MX 2022006891A
- Authority
- MX
- Mexico
- Prior art keywords
- adc
- antagonist
- liv1
- combination therapy
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
La presente descripción se refiere, en general, a métodos para tratar cánceres que expresan LIV-1 que comprenden administrar un conjugado anticuerpo-fármaco anti-LIV-1 (LIV-1-ADC) en combinación con un antagonista de PD-1, como un anticuerpo anti-PD-1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962945885P | 2019-12-09 | 2019-12-09 | |
US202063031528P | 2020-05-28 | 2020-05-28 | |
US202063076664P | 2020-09-10 | 2020-09-10 | |
US202063110692P | 2020-11-06 | 2020-11-06 | |
PCT/US2020/063976 WO2021119105A1 (en) | 2019-12-09 | 2020-12-09 | Combination therapy with liv1-adc and pd-1 antagonist |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022006891A true MX2022006891A (es) | 2022-09-09 |
Family
ID=74046208
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022006891A MX2022006891A (es) | 2019-12-09 | 2020-12-09 | Terapia combinada con liv1-adc y antagonista de pd-1. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20210228676A1 (es) |
EP (1) | EP4072583A1 (es) |
JP (1) | JP2023506187A (es) |
KR (1) | KR20220114002A (es) |
CN (1) | CN115066259A (es) |
AU (1) | AU2020399976A1 (es) |
BR (1) | BR112022011268A2 (es) |
CA (1) | CA3164124A1 (es) |
MX (1) | MX2022006891A (es) |
TW (1) | TW202133887A (es) |
WO (1) | WO2021119105A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA45324A (fr) | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1210428E (pt) | 1999-08-23 | 2015-07-21 | Genetics Inst Llc | Pd-1, um recetor para b7-4 e suas utilizações |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
BR122018071968B8 (pt) | 2003-11-06 | 2021-07-27 | Seattle Genetics Inc | conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga |
CA2970873C (en) | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
EP3222634A1 (en) | 2007-06-18 | 2017-09-27 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010027423A2 (en) | 2008-08-25 | 2010-03-11 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
WO2012078688A2 (en) | 2010-12-06 | 2012-06-14 | Seattle Genetics, Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
EP2992017B1 (en) | 2013-05-02 | 2020-11-18 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
JP6563906B2 (ja) | 2013-05-31 | 2019-08-21 | ソレント・セラピューティクス・インコーポレイテッドSorrento Therapeutics, Inc. | Pd−1に結合する抗原結合蛋白質 |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
CR20160319A (es) | 2013-12-12 | 2016-11-08 | Jiangsu Hengrui Medicine Co | Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
MA45324A (fr) * | 2016-03-15 | 2019-01-23 | Seattle Genetics Inc | Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique |
SI3464368T1 (sl) | 2016-06-02 | 2023-10-30 | Bristol-Myers Squibb Company | Uporaba protitelesa anti-pd-1 v kombinaciji s protitelesom anti-cd30 pri zdravljenju limfoma |
KR20200090838A (ko) * | 2017-12-01 | 2020-07-29 | 시애틀 지네틱스, 인크. | 유방암 치료를 위한 인간화된 항-liv1 항체 |
-
2020
- 2020-12-09 AU AU2020399976A patent/AU2020399976A1/en active Pending
- 2020-12-09 BR BR112022011268A patent/BR112022011268A2/pt not_active Application Discontinuation
- 2020-12-09 CN CN202080092300.0A patent/CN115066259A/zh active Pending
- 2020-12-09 KR KR1020227023382A patent/KR20220114002A/ko unknown
- 2020-12-09 JP JP2022535539A patent/JP2023506187A/ja active Pending
- 2020-12-09 TW TW109143461A patent/TW202133887A/zh unknown
- 2020-12-09 US US17/116,543 patent/US20210228676A1/en active Pending
- 2020-12-09 MX MX2022006891A patent/MX2022006891A/es unknown
- 2020-12-09 CA CA3164124A patent/CA3164124A1/en active Pending
- 2020-12-09 WO PCT/US2020/063976 patent/WO2021119105A1/en unknown
- 2020-12-09 EP EP20829486.8A patent/EP4072583A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20220114002A (ko) | 2022-08-17 |
JP2023506187A (ja) | 2023-02-15 |
EP4072583A1 (en) | 2022-10-19 |
CA3164124A1 (en) | 2021-06-17 |
BR112022011268A2 (pt) | 2022-09-06 |
TW202133887A (zh) | 2021-09-16 |
CN115066259A (zh) | 2022-09-16 |
WO2021119105A1 (en) | 2021-06-17 |
US20210228676A1 (en) | 2021-07-29 |
AU2020399976A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023001686A (es) | Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anti-cdh6. | |
MX2019008208A (es) | Métodos para tratar el cáncer con anticuerpos anti-tim-3. | |
MY202279A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
MX2019002474A (es) | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. | |
MA39906A (fr) | Polythérapies pour le traitement du cancer | |
PH12016500349A1 (en) | Anti-prlr antibodies and uses thereof | |
MX2019012464A (es) | Terapia combinada con un conjugado de anticuerpo y farmaco anti-axl. | |
MX2020010604A (es) | Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1). | |
TN2015000050A1 (en) | Methods of treating a tauopathy | |
WO2019006005A3 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MELANOMA | |
MX2018005544A (es) | Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer. | |
MX2021004226A (es) | Terapia combinada contra el cáncer. | |
WO2018208954A3 (en) | Peptidomimetic macrocycles and uses thereof | |
MX2023002805A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicacion de los mismos. | |
AU2018314227A8 (en) | Treatment of triple negative breast cancer or colorectal cancer with liver metastases with an anti PD-L1 antibody and an oncolytic virus | |
MX2021004709A (es) | Metodo y medicamento para tratar cancer insensible a inhibidor de se?alizacion de pd-1/pd-l1. | |
MX2021001832A (es) | Conjugados para su uso en metodos de tratamiento del cancer. | |
MX2022006891A (es) | Terapia combinada con liv1-adc y antagonista de pd-1. | |
ZA202200905B (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
MX2017013358A (es) | Métodos para tratar el cáncer. | |
CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
MX2021003734A (es) | Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30. | |
MX2021010313A (es) | Dosificacion para el tratamiento con anticuerpos anti-tigit y anti-cd20 o anti-cd38. | |
MX2019014291A (es) | Metodo de tratamiento. |